Evidence map›Paper›PMID 38318184›Full record

ArticleFrontiers in immunology2024

Highly heterogenous humoral immune response in Lyme disease patients revealed by broad machine learning-assisted antibody binding profiling with random peptide arrays.

L Kelbauskas, J B Legutki, N W Woodbury

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

L KelbauskasBiodesign Institute, Arizona State University, Tempe, AZ, United States.
J B LegutkiBiodesign Institute, Arizona State University, Tempe, AZ, United States.
N W WoodburyBiodesign Institute, Arizona State University, Tempe, AZ, United States.

Funding

Machine learning-based development of serologic test for acute Lyme disease diagnosisR43AI162473 · NIAID · BIOMORPH TECHNOLOGIES LLC · PI KELBAUSKAS, LAIMONAS, LEGUTKI, JOSEPH BARTEN · 2021 to 2021
$300k
NIAID NIH HHS R43 AI162473
6 · The paper itself

Abstract

Introduction: Lyme disease (LD), a rapidly growing public health problem in the US, represents a formidable challenge due to the lack of detailed understanding about how the human immune system responds to its pathogen, the Methods: This study was designed to perform a broad profiling of the entire repertoire of circulating antibodies in human sera at the single-individual level using planar arrays of short linear peptides with random sequences. The peptides sample sparsely, but uniformly the entire combinatorial sequence space of the same length peptides for profiling the humoral immune response to a Results: The study revealed substantial variability in antibody binding profiles between individual LD patients even to the same antigen (VlsE protein) and strong similarity between individuals diagnosed with Lyme disease and healthy controls from the areas endemic to LD suggesting a high prevalence of seropositivity in endemic healthy control. Discussion: This work demonstrates the utility of the approach as a valuable analytical tool for agnostic profiling of humoral immune response to a pathogen.

Indexed as

Borrelia burgdorferiLyme DiseaseBacterial ProteinsHumansImmunity, HumoralPeptidesBacterial ProteinsPeptidesantibody profilinghumoral immune responseLyme disease (LD)machine learningpeptide arraypredictive modeling

Identifiers

PMID38318184
PMCPMC10838964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.